Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 14/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30892640 | 0.91 | CTSK (0.41) | CTSKBCHEACHE | |
| SCHEMBL23646865 | 0.85 | FOLH1 (0.57) | FOLH1 | |
| SCHEMBL23646866 | 0.85 | FOLH1 (0.57) | FOLH1 | |
| SCHEMBL22228930 | 0.84 | FOLH1 (0.52) | FOLH1NAALAD2 | |
| SCHEMBL22228931 | 0.84 | FOLH1 (0.52) | FOLH1NAALAD2 | |
| SCHEMBL19743102 | 0.82 | FOLH1 (0.46) | FOLH1 | |
| SCHEMBL19743136 | 0.81 | ALB (0.48) | FOLH1 | |
| SCHEMBL19743137 | 0.81 | ALB (0.48) | FOLH1 | |
| SCHEMBL19743134 | 0.81 | FOLH1 (0.50) | FOLH1 | |
| SCHEMBL19743135 | 0.81 | FOLH1 (0.50) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140971-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSTY | 2024-05-02 | — | — | US | disclosed |
| US-20200231614-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231614-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | PSMA7, PSMA6, PSMA1 | FOLH1 28/4885CTSK 264/4885BCHE 1009/4885 |
| US-20240140971-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | PSMA3, PSMA6, PSMA7 | FOLH1 10/4885CTSK 571/4885BCHE 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.